Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial

This publication has 14 references indexed in Scilit:

• Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials
  American Heart Journal, 2003
• Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention
  JAMA, 2003
• Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status
  Circulation, 2001
• Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization
  Journal of the American College of Cardiology, 1997
• Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
  New England Journal of Medicine, 1997
• In-Hospital and One-Year Economic Outcomes After Coronary Stenting or Balloon Angioplasty
  Circulation, 1995
• Direct thrombin inhibitors in cardiovascular medicine.
  Circulation, 1994
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
  Journal of Clinical Investigation, 1990
• Effect of heparin on platelet count and platelet aggregation
  American Journal of Hematology, 1987